CoChat

Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response

Open access
Ahn, Jinwoo, Urist, Marshall, Prives, Carol · 2003 · Journal of Biological Chemistry

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Abstract

Cdc25C and p53 have been reported to be physiological targets of checkpoint kinase 2 (Chk2). Surprisingly, although Chk2 purified from DNA damage sustaining cells has dramatically increased ability to phosphorylate Cdc25C when compared with untreated cells, its ability to phosphorylate p53 is weak before treatment, and there is no increase in its activity toward p53 after DNA damage by gamma irradiation or the radiomimetic agent neocarzinostatin. Furthermore, introduction of Chk2 short interfering RNA into three different human tumor cell lines leads to marked reduction of Chk2 protein, but p53 is still stabilized and active after DNA damage. The results with Chk1 short interfering RNA indicate as well that Chk1 does not play a role in human p53 stabilization after DNA damage. Thus, Chk1 and Chk2 are unlikely to be regulators of p53 in at least some human tumor cells. We discuss our results in the context of previous findings demonstrating a requirement for Chk2 in p53 stabilization and activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m213185200

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
FIG. 2 Failure of Chk2 to be stimulated by NCS to phosphorylate different versions of p53. HA-Chk2 (6 ng) immunopurified after no treatment or NCS treatment as indicated were incubated with the following. A , 0.1, 0.25, 1.0, and 2.0 𝛍 g of GST-Cdc25C (200-256). B , 0.1, 0.25, 1.0, and 2.0 𝛍 g of GST-p53 (182). C , 0.45, 0.9, 1.8, and 3.6 𝛍 g of GSTp53 (97-363). D , 0.12, 0.24, 0.48, and 0.96 𝛍 g of GST-p53 ( WT ). E , 0.1, 0.25, 1.0, and 2.0 𝛍 g of His-tagged p53 ( WT ). The reaction mixtures were analyzed as described for Fig. 1 A . In autoradiograms the K arrow indicates kinase autophosphorylation, and the S arrow is substrate (Cdc25C in A ; p53 constructs in B-E ).
FIG. 2 Failure of Chk2 to be stimulated by NCS to phosphorylate different versions of p53. HA-Chk2 (6 ng) immunopurified after no treatment or NCS treatment as indicated were incubated with the following. A , 0.1, 0.25, 1.0, and 2.0 𝛍 g of GST-Cdc25C (200-256). B , 0.1, 0.25, 1.0, and 2.0 𝛍 g of GST-p53 (182). C , 0.45, 0.9, 1.8, and 3.6 𝛍 g of GSTp53 (97-363). D , 0.12, 0.24, 0.48, and 0.96 𝛍 g of GST-p53 ( WT ). E , 0.1, 0.25, 1.0, and 2.0 𝛍 g of His-tagged p53 ( WT ). The reaction mixtures were analyzed as described for Fig. 1 A . In autoradiograms the K arrow indicates kinase autophosphorylation, and the S arrow is substrate (Cdc25C in A ; p53 constructs in B-E ).CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
FIG. 5 Specific down-regulation of Chk1 and Chk2. HCT116 cells transfected with the indicated siRNAs were either not treated ( -) or treated with 500 ng/ml NCS for either 5 or 15 h as indicated. The extracts were resolved by SDS-PAGE and subjected to immunoblotting with anti-Chk1, -Chk2, -actin, or -Cdc25C Ser(P) 216 antibodies as indicated. Luc , luciferase.
FIG. 5 Specific down-regulation of Chk1 and Chk2. HCT116 cells transfected with the indicated siRNAs were either not treated ( -) or treated with 500 ng/ml NCS for either 5 or 15 h as indicated. The extracts were resolved by SDS-PAGE and subjected to immunoblotting with anti-Chk1, -Chk2, -actin, or -Cdc25C Ser(P) 216 antibodies as indicated. Luc , luciferase.CC-BY · From the PDF
FIG. 6 Down-regulation of Chk1 or Chk2 do not affect p53 levels in cells with or without DNA damage. HCT116 transfected with the indicated siRNAs were either not treated ( -) or treated with 500 ng/ml NCS for either 0.5 and 3 h ( A ) or 5 and 15 h ( B ) as indicated. The extracts were resolved by SDS-PAGE and subjected to immunoblotting with anti-Chk1, -Chk2, -p53, actin, p21, HDM2, p53-induced gene 3 or Cdc25C Ser(P) 216 antibodies as indicated. The bottom panels show quantitation of fold p53 induction relative to lane 1 (control transfected untreated cells) and normalized to actin using Image J software (National Institutes of Health). C , HT-29 cells with mutant p53 were transfected with siRNA targeting luciferase ( Luc ) or Chk2 and either untreated ( -) or exposed to 10 Gy IR ( + ) and collected after 30 min. The cell extracts were resolved by SDS-PAGE and immunoblotted with anti-Chk2, p53, anti-phospho-p53 Ser(P) 20 or actin antibodies as indicated on the right . IR , irradiation.
FIG. 6 Down-regulation of Chk1 or Chk2 do not affect p53 levels in cells with or without DNA damage. HCT116 transfected with the indicated siRNAs were either not treated ( -) or treated with 500 ng/ml NCS for either 0.5 and 3 h ( A ) or 5 and 15 h ( B ) as indicated. The extracts were resolved by SDS-PAGE and subjected to immunoblotting with anti-Chk1, -Chk2, -p53, actin, p21, HDM2, p53-induced gene 3 or Cdc25C Ser(P) 216 antibodies as indicated. The bottom panels show quantitation of fold p53 induction relative to lane 1 (control transfected untreated cells) and normalized to actin using Image J software (National Institutes of Health). C , HT-29 cells with mutant p53 were transfected with siRNA targeting luciferase ( Luc ) or Chk2 and either untreated ( -) or exposed to 10 Gy IR ( + ) and collected after 30 min. The cell extracts were resolved by SDS-PAGE and immunoblotted with anti-Chk2, p53, anti-phospho-p53 Ser(P) 20 or actin antibodies as indicated on the right . IR , irradiation.CC-BY · From the PDF
FIG. 7 Down-regulation of Chk1 or Chk2 in MCF-7 and RKO cell lines. A , top panel , MCF-7 cells were transfected with the indicated siRNAs and treated or not ( -) with 500 ng/ml NCS for either 0.5 or 2.5 h. The extracts were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against Chk1, Chk2, p53, actin, or Hdm2 as indicated on right. B , top panel , RKO cells were treated as in A except that cells were exposed to 500 ng/ml NCS for 5 h. A and B , bottom panels , fold p53 induction was quantitated relative to lane 1 in each case (control transfected untreated cells) and normalized to actin using Image J software (National Institutes of Health). Luc , luciferase.
FIG. 7 Down-regulation of Chk1 or Chk2 in MCF-7 and RKO cell lines. A , top panel , MCF-7 cells were transfected with the indicated siRNAs and treated or not ( -) with 500 ng/ml NCS for either 0.5 or 2.5 h. The extracts were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against Chk1, Chk2, p53, actin, or Hdm2 as indicated on right. B , top panel , RKO cells were treated as in A except that cells were exposed to 500 ng/ml NCS for 5 h. A and B , bottom panels , fold p53 induction was quantitated relative to lane 1 in each case (control transfected untreated cells) and normalized to actin using Image J software (National Institutes of Health). Luc , luciferase.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 5

  1. Ahn, 2000, Cancer Res., 60, 5934
  2. Dumaz, 2001, Biochem. J., 359, 459, 10.1042/bj3590459 · doi:10.1042/bj3590459 · Paper page
  3. Vahteristo, 2001, Cancer Res., 61, 5718
  4. Matsuoka, 2001, Cancer Res., 61, 5362
  5. Waldman, 1995, Cancer Res., 55, 5187

Cited by

See all 101

Metadata

Authors
Ahn, J., Urist, M., & Prives, C.
Affiliations
Columbia University (US)
Corresponding author
Prives, Carol
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2003-06
Volume
278
Issue
23
Pages
20480-20489
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2114647652
Cited by
99
References
63
Citations by year
2026: 1 · 2021: 1 · 2020: 1 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 4 · 2012: 2
FWCI
7.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (CA87497)
  • National Cancer Institute (CA-87497, P01CA087497)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
checkpoint kinase 2, Chk2, p53, Cdc25C, DNA damage response, p53 stabilization, Chk1, protein phosphorylation, gamma irradiation, neocarzinostatin, cancer cell lines, siRNA
MeSH terms
Checkpoint Kinase 1, Colonic Neoplasms, DNA Damage, Gamma Rays, Humans, Zinostatin, Phosphorylation, Protein Kinases, Substrate Specificity, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Nucleic Acid Synthesis Inhibitors, cdc25 Phosphatases, Checkpoint Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response. https://app.cochat.ai/papers/10.1074/jbc.m213185200
The paper
Ahn, J., Urist, M., & Prives, C. (2003). Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m213185200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.